GeneDx Holdings Corp.
No SEC Form 4 filings for $WGS in the last 30 days.
Investing.com’s after-hours movers report highlights Palantir (PLTR) up 10% after Q2 EPS of $0.41 and $1.94B revenue, with 2026 revenue guidance raised to $8.15–$8.158B. Snap (SNAP) rose 9.6% on Q2 revenue $1.6B and Q3 guidance $1.7–$1.74B. Backblaze (BLZE) gained 16% on Q2 beat and raised 2026 revenue to $172–$174M. ON (ON) +5%, ICHR -11%, WGS -7%, WHR -4%.
GeneDx Holdings Corp. (WGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026pressrele.htm EX-99.1 Document Exhibit 99.1 GeneDx Reports Second Quarter 2026 Financial Results • Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue • Reported exome and genome volume growth of
GeneDx Holdings (formerly Sema4, NASDAQ: WGS) and former officers filed responses in a federal securities class action over alleged overstated capabilities of Centrellis, an AI-molecular and phenotypic data system. The parties settled for about $4.8M to resolve claims of fraud tied to a 2022 GeneDx acquisition valued near $623M. Court filings were submitted July 24, 2026.
Over the past 7 days, alphai's AI scored 2 news stories mentioning WGS (GeneDx Holdings Corp.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent WGS coverage spans earnings, financial news and insider activity.
Loss widening plus slightly light Q3 revenue guidance likely outweigh the revenue beat for sentiment.
The 8-K provides fresh quarterly performance plus reaffirmed full-year guidance and new third-quarter guidance, which can drive near-term estimate revisions.
Settlement adds legal overhang around prior AI-related disclosures and governance, potentially pressuring sentiment and litigation risk premium.
The key trade input is the analyst’s view that valuation is low after operational improvements and governance changes.
The article frames a guidance reset tied to reimbursement softness and segment weakness, which can pressure near-term estimates and sentiment.
alphai scores every news story that mentions WGS with an AI model for sentiment and relevance, and aggregates insider trades from GeneDx Holdings Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Investing.com’s after-hours movers report highlights Palantir (PLTR) up 10% after Q2 EPS of $0.41 and $1.94B revenue, with 2026 revenue guidance raised to $8.15–$8.158B. Snap (SNAP) rose 9.6% on Q2 revenue $1.6B and Q3 guidance $1.7–$1.74B. Backblaze (BLZE) gained 16% on Q2 beat and raised 2026 revenue to $172–$174M. ON (ON) +5%, ICHR -11%, WGS -7%, WHR -4%.
6 min readGeneDx Holdings Corp. (WGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026pressrele.htm EX-99.1 Document Exhibit 99.1 GeneDx Reports Second Quarter 2026 Financial Results • Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue • Reported exome and genome volume growth of
6 min readGeneDx Holdings (formerly Sema4, NASDAQ: WGS) and former officers filed responses in a federal securities class action over alleged overstated capabilities of Centrellis, an AI-molecular and phenotypic data system. The parties settled for about $4.8M to resolve claims of fraud tied to a 2022 GeneDx acquisition valued near $623M. Court filings were submitted July 24, 2026.
5 min readInvesting.com reports BTIG analyst Mark Massaro previewed seven specialty labs and diagnostics stocks as valuations rise. BTIG rates Guardant Health (GH) Buy, $190 target; Natera (NTRA) Buy, $290; BillionToOne (BLLN) Buy, $142; GeneDx (WGS) Buy, $90; Adaptive Biotechnologies (ADPT) Buy, $24; Tempus AI (TEM) Buy, $80; Caris (CAI) Buy, $32, with Q2 expectations and volume or catalyst updates.
5 min readAn Alger Small Cap Focus Fund Q2 2026 investor letter discussed GeneDx Holdings Corp. (NASDAQ:WGS), a genomics diagnostics company. The article says WGS closed at $60.65 on July 20, 2026 and that Q1 2026 revenue was $102.3 million, $12 million below expectations, with volumes up 33% YoY. It notes management lowered full-year guidance after revenue missed forecasts.
5 min readKessler Topaz Meltzer & Check said a securities-fraud class action was filed against GeneDx Holdings Corp. (NASDAQ: WGS) in the District of Connecticut. The class period runs April 16, 2025 to May 4, 2026, with an Aug. 3, 2026 lead-plaintiff deadline. Allegations center on statements about the viability of GeneDx’s up-to-$51 million acquisition of Fabric Genomics and a May 4, 2026 impairment write-off of $31.3 million.
4 min readLevi & Korsinsky announced a securities class action against GeneDx Holdings Corp. (NASDAQ:WGS) for alleged securities fraud. The suit covers purchases between Apr. 16, 2025 and May 4, 2026, alleging misleading statements about the Fabric acquisition’s expected financial and operational benefits. The complaint claims shares traded at inflated prices.
2 min readGeneDx Holdings Corp. (WGS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. wgs-20260618 0001818331 false 0001818331 2026-06-18 2026-06-18 0001818331 us-gaap:CommonClassAMember 2026-06-18 2026-06-18 0001818331 us-gaap:WarrantMember 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursua
2 min readFeeley Kevin (CHIEF FINANCIAL OFFICER) sold 3,729 shares of GeneDx Holdings Corp. (WGS) at an average of $60.77 ($59.75–$61.50, $0.23M total) across 3 trades on 2026-06-16.
2 min readStueland Katherine (CHIEF EXECUTIVE OFFICER) sold 10,501 shares of GeneDx Holdings Corp. (WGS) at an average of $60.77 ($59.75–$61.50, $0.64M total) across 3 trades on 2026-06-16.
2 min read
